

AMENDMENTS TO THE CLAIMS

Claims 2-5, 7-14, 17-22 and 26 are amended, as shown below. A complete listing of the claims in this case, with their status, is shown below.

1. **(CANCELLED)**
2. **(Currently amended)** ~~The composition of claim 25, comprising~~ The method of claim 20, wherein the composition comprises alloactivated lymphocytes from at least two human donors different from the patient.
3. **(Currently amended)** ~~The composition of claim 2, comprising~~ The method of claim 2, wherein the composition comprises alloactivated lymphocytes from at least three human donors different from the patient.
4. **(Currently amended)** ~~The composition of claim 3, comprising~~ The method of claim 2, wherein the composition comprises alloactivated lymphocytes from at least four human donors different from the patient.
5. **(Currently amended)** ~~The composition of claim 25, further comprising~~ The method of claim 20, wherein the composition comprises lymphocytes from the patient that have been inactivated.
6. **(CANCELLED)**
7. **(Currently amended)** ~~The composition of claim 6,~~ The method of claim 22, wherein the tumor-associated antigen is expressed on a tumor cell present in the composition.
8. **(Currently amended)** ~~The composition of claim 25, wherein the lymphocytes are alloactivated~~ The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with human cells *ex vivo* expressing HLA-DR antigens that are allogeneic to both HLA-DR antigens on the lymphocytes.
9. **(Currently amended)** ~~The composition of claim 25, wherein the lymphocytes are alloactivated~~ The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with allogeneic human cells *ex vivo* for a time whereby the lymphocytes become sufficiently alloactivated to be effective in eliciting an anti-tumor immunological response when administered to a human.
10. **(Currently amended)** ~~The composition of claim 25, wherein the lymphocytes are alloactivated~~ The method of claim 20, wherein the lymphocytes in the composition have been alloactivated by coculturing with allogeneic human cells *ex vivo* for a time whereby the lymphocytes become sufficiently alloactivated to be effective in extending life expectancy or causing progressive reduction in tumor mass when administered to a human having a tumor.

11. *(Currently amended)* ~~The composition of claim 25, wherein the lymphocytes are alloactivated~~
The method of claim 20, wherein the lymphocytes in the composition have been alloactivated
by coculturing with allogeneic human cells *ex vivo* until about the time when secretion of IFN- γ by
the alloactivated lymphocytes is highest.
12. *(Currently amended)* ~~The composition of claim 25, wherein the lymphocytes are alloactivated~~
The method of claim 20, wherein the lymphocytes in the composition have been alloactivated
by coculturing with allogeneic human cells *ex vivo* until about the time when secretion of IL-2 by
the alloactivated lymphocytes is highest.
13. *(Currently amended)* ~~The composition of claim 25, wherein the lymphocytes are alloactivated~~
The method of claim 20, wherein the lymphocytes in the composition have been alloactivated
by coculturing with allogeneic human cells *ex vivo* for between about 12 hours and 5 days.
14. *(Currently amended)* ~~The composition of claim 25, wherein the lymphocytes are alloactivated~~
The method of claim 20, wherein the lymphocytes in the composition have been alloactivated
by coculturing with allogeneic human cells *ex vivo* for between about 24 and 72 hours.
15. *(Cancelled)*
16. *(Cancelled)*
17. *(Currently amended)* ~~The device of claim 16, which is~~ method of claim 20, wherein the
composition is administered using an injection needle.
18. *(Currently amended)* ~~The device of claim 16, which is suitable for positioning by~~ method of
claim 20, wherein the composition is administered using ultrasound guided endoscopy.
19. *(Currently amended)* A method for treating cancer in a human patient, comprising administering
to the patient ~~the pharmaceutical composition of claim 25~~
a pharmaceutical composition comprising alloactivated lymphocytes from a donor who is
unrelated to the patient in a compatible pharmaceutical excipient.
20. *(Currently amended)* A method for eliciting an anti-tumor immunological response in a human
patient, comprising administering to the patient ~~the pharmaceutical composition of claim 25~~
a pharmaceutical composition comprising alloactivated lymphocytes from a donor who is
unrelated to the patient in a compatible pharmaceutical excipient.
21. *(Currently amended)* A method for treating cancer in a human patient, comprising administering
to the patient ~~the pharmaceutical composition of claim 6~~
a pharmaceutical composition comprising stimulated lymphocytes and a tumor associated
antigen in a compatible pharmaceutical excipient.

22. **(Currently amended)** A method for eliciting an anti-tumor immunological response in a human patient, comprising administering to the patient ~~the pharmaceutical composition of claim 6~~ **a pharmaceutical composition comprising stimulated lymphocytes and a tumor associated antigen in a compatible pharmaceutical excipient.**
23. **(Original)** The method of claim 19, wherein the pharmaceutical composition is administered at or around the site of a solid tumor in the patient.
24. **(Original)** The method of claim 21, wherein the pharmaceutical composition is administered at a site distal to the tumor.
25. **(CANCELLED)**
26. **(Currently amended)** ~~The composition of claim 6, which~~ **The method of claim 22, wherein the composition** is formulated for subcutaneous or intramuscular administration, wherein administration of the composition at a site distal to the tumor elicits an immunological response by the patient against the tumor.